WOC 2018

Ellex invites you to join us in Barcelona for the 2018 meeting of the World Ophthalmology Congress (WOC), 16-19 June. Visit the Ellex Exhibit #2020 to connect with expert faculty across the disciplines of MIGS, Selective Light Therapy and Laser Floater Treatment. Another highlight will be Ellex’s proprietary 2RT® Retinal Rejuvenation Therapy for early AMD: don’t miss the opportunity to meet 2RT® lead clinical investigator, Prof. Robyn Guymer.

GLAUCOMA EVENTS AT WOC 2018

MIGS Meet the Expert / Wet Lab

Ellex Exhibit #2020

Join us at the Ellex Exhibit #2020 to meet world-renowned cataract surgeon and ABiC™ expert David Lubeck, MD. Dr. Lubeck will share his clinical tips and surgical pearls for ABiC. He will also host a series of hands-on Wet Labs featuring Ellex’s iTrack™ technology.

Speakers

David D. Lubeck
MD (USA)

Session 1

Sunday 17 June
10.00 - 11.00am

Session 2

Monday 18 June
10.00 - 11.00am

Note: these sessions are not affiliated with the official program of the WOC 2018.

MIGS Myth Busters

Ellex Exhibit #2020

Join Ellex for a “Myth Busters” Session at the Ellex Exhibit #2020 to hear a panel of leading SLT and MIGS practitioners address some of the misconceptions surrounding the use of SLT and ABiC™ in clinical practice.

Speakers

Paul I. Singh
MD (USA)
David D. Lubeck
MD (USA)

Session 1

Sunday 17 June
3.30 - 4.00pm

Session 2

Monday 18 June
3.30 - 4.00pm

Download the invitation

Note: these sessions are not affiliated with the official program of the WOC 2018.

I have been a practicing glaucoma specialist for over 10 years. The introduction of ABiC has completely changed my glaucoma treatment paradigm. Not only has ABiC proven itself to be highly effective in lowering IOP and reducing medication dependence, it also offers an excellent safety profile. There is no manipulation of the conjunctiva, and the post-op recovery resembles that of cataract surgery.

Mahmoud A. Khaimi, MD (Dean McGee Eye Institute, University of Oklahoma)

MIGS FROM ELLEX

ABiC™ is the only ab-interno minimally invasive glaucoma surgery (MIGS) procedure currently available that comprehensively addresses blockages in the collector channels and flushes outflow channels without damaging tissue and without leaving behind a stent or shunt. Intuitive and efficient, ABiC™ can be performed as a stand-alone procedure, or it can be combined with cataract surgery. ABiC™ can also be used in conjunction with other MIGS devices or treatments — and, as an atraumatic procedure, it does not preclude future treatment options.

Learn more about ABiC
SLT has the potential to become the go-to glaucoma treatment. Not only can SLT eliminate or at least reduce the need for drops, it can help to preserve vision and delay or even prevent complicated, invasive surgical interventions.

Savak “Sev” Teymoorian, MD, MBA (Harvard Eye Associates, California)

SLT FROM ELLEX

Ellex’s proprietary SLT technology delivers superior energy control, a sharp-edged aiming beam and the industry’s fastest firing rate of three shots per second. It's a capability that's being used every day by thousands of physicians around the world to visualize the trabecular meshwork in greater detail, to constantly optimize the system's output, and to perform procedures faster and with improved accuracy, delivering better patient outcomes - reliably, accurately and safely.

Learn more about SLT

LFT EVENTS AT WOC 2018

Meet the LFT Expert

Ellex Exhibit #2020

Join us at the Ellex Exhibit #2020 to meet LFT expert Dr. Paul I. Singh during a series of “Meet the Expert” sessions. Having performed more than 3000 LFT procedures, Dr. Singh is an expert in the treatment of symptomatic floater patients. Dr. Singh will address his surgical pearls and clinical tips, highlighting the benefits of Reflex Technology™ for laser-based floater treatment.

Speakers

Paul I. Singh
MD (USA)

Session 1

Sunday 17 June
10.00 - 11.00am

Session 2

Monday 18 June
10.00 - 11.00am

Note: these sessions are not affiliated with the official program of the WOC 2018.

LFT Myth Busters

Ellex Exhibit #2020

Join Ellex for a “Myth Busters” Session at the Ellex Exhibit #2020 to hear a panel of leading LFT practitioners address some of the misconceptions regarding laser-based floater treatment.

Speakers

Paul I. Singh
MD (USA)
David D. Lubeck
MD (USA)
Andrzej Dmitriew
MD (USA)

Session 1

Sunday 17 June
4.00 - 4.30pm

Session 2

Monday 18 June
4.00 - 4.30pm

Download the invitation

Note: these sessions are not affiliated with the official program of the WOC 2018.

I adopted laser floater treatment for the symptomatic floater patients just over three years ago. More than 3,000 procedures later, I have been astounded by the positive effect it has had on my patients. I now also fully appreciate the negative impact floaters can have on patients’ quality of life. When looking at the results in my own clinic, more than 90% of patients indicate that they are satisfied with their improvement in daily visual functioning as a result of undergoing the procedure.

Paul I. Singh, MD (Eye Centers of Racine and Kenosha)

LFT FROM ELLEX

Ellex was the first company to pioneer a laser designed specifically for the treatment of floaters. Our Reflex Technology™ features True Coaxial Illumination™ (TCI), on and off-axis modes, a precise green aiming beam and a superior energy beam profile — all within a unique slit lamp illumination tower design that converges and focuses the physician’s sight line, target illumination and treatment beam into one optical path. It’s an approach that maximizes focusing accuracy and provides a safe and highly effective tool for the treatment of vitreous opacities.

Learn more about LFT

Retinal Rejuvenation at WOC 2018

Meet the 2RT Expert

Ellex Exhibit #2020

Join us at the Ellex Exhibit #2020 to meet lead clinical investigator for 2RT®, Prof. Robyrn Guymer, and 2RT® clinician Prof. Andrea Cusumano. Both Prof. Guymer and Prof. Cusumano will provide their clinical insight into the mechanism of 2RT® and its clinical application as an intervention for early age-related macular degeneration (AMD).

Speakers

Robyn Guymer
MB, BS, PhD, FRANZCO (Australia)
Andrea Cusumano
MD, PhD (Italy)

Session 1

Sunday 17 June
10.00 - 11.00am

Session 2

Monday 18 June
10.00 - 11.00am

Note: these sessions are not affiliated with the official program of the WOC 2018.

2RT Myth Busters

Ellex Exhibit #2020

Join Ellex for a “Myth Busters” Session at the Ellex Exhibit #2020 to hear a panel of leading 2RT® researchers and practitioners address some of the misconceptions surrounding 2RT® Retinal Rejuvenation Therapy in the treatment of early AMD.

Speakers

Robyn Guymer
MB, BS, PhD, FRANZCO (Australia)
Andrea Cusumano
MD, PhD (Italy)
John Marshall
PhD, FRCPath, FRCOphth (Hon) (UK)

Session 1

Sunday 17 June
3.00 - 3.30pm

Session 2

Monday 18 June
3.00 - 3.30pm

Download the invitation

Note: these sessions are not affiliated with the official program of the WOC 2018.

2RT FROM ELLEX

Retinal Rejuvenation Therapy, 2RT®, stimulates a biological healing process that results in cellular rejuvenation, renewing the entire transport mechanism of the retina and improving the hydraulic conductivity of Bruch’s membrane. This rejuvenation process preserves or improves functional vision and reduces disease progression — without causing collateral damage to the overlying photoreceptor rods and cones of the retina. 2RT® offers the potential to intervene earlier in the treatment of AMD before significant vision loss has occurred to slow or reverse the degeneration process.

Learn more about 2RT

Ellex is the manufacturer of 2RT®. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex does not accept any responsibility for use of the system outside of these indications. The material presented herein may include the views or recommendations of third parties and does not necessarily reflect the views of Ellex Medical Pty Ltd.

2RT® has a CE Mark (Conformité Européenne) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function.

2RT® has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market release for the treatment of Clinically Significant Macula Edema (CSME).